Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.

ABSTRACT:

Purpose

To determine the systemic exposure to cisplatin and paclitaxel after adjuvant intraperitoneal administration in patients with advanced ovarian cancer who underwent primary debulking surgery. This could provide an explanation for the high incidence of systemic adverse events associated with this treatment regimen.

Methods

This is a prospective pharmacokinetic study in patients with newly diagnosed advanced ovarian cancer who were treated with intraperitoneal administered cisplatin and paclitaxel. Plasma and peritoneal fluid samples were obtained during the first treatment cycle. The systemic exposure to cisplatin and paclitaxel was determined and compared to previously published exposure data after intravenous administration. An exploratory analysis was performed to i

SUBMITTER: de Jong LAW 

PROVIDER: S-EPMC10033566 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature